News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elixir Medical Goes Head-to-Head Against Medtronic, Inc. (MDT) With Its DESyne Nx DES Study



5/14/2013 9:01:08 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Elixir Medical Corporation begins enrolling patients in a new trial to compare its DESyne Nx Novolimus-eluting coronary stent system to Medtronic's equivalent. With a green-light from the FDA, Elixir Medical Corporation will move forward with its Excella III pivotal trial to review its DESyne Nx Novolimus-eluting coronary stent system. Elixir plans to enroll patients at 50 clinical locations and will use the trial results to support its upcoming premarket approval application. The Excella III study will compare DeSyneNx treatment to Medtronic's (NYSE:MDT) Resolute Zotarolimus-eluting coronary stent system. Results in the Excella II trial last year resulted in CE Mark approval for Elixir's treatment.

Help employers find you! Check out all the jobs and post your resume.

Read at MassDevice


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES